Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease

Seyma Bahdoudi, Ikram Ghouili, Mansour Hmiden, Jean-Luc do Rego, Benjamin Lefranc, Jérôme Leprince, Julien Chuquet, Jean-Claude do Rego, Ann-Britt Marcher, Susanne Mandrup, Hubert Vaudry, Marie-Christine Tonon, Mohamed Amri, Olfa Masmoudi-Kouki, David Vaudry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopamine (DA) neurons through apoptotic, inflammatory and oxidative stress mechanisms. The octadecaneuropeptide (ODN) is a diazepam-binding inhibitor (DBI)-derived peptide, expressed by astrocytes, which protects neurons against oxidative cell damages and apoptosis in an in vitro model of PD. The present study reveals that a single intracerebroventricular injection of 10 ng ODN 1 h after the last administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) prevented the degeneration of DA neurons induced by the toxin in the substantia nigra pars compacta of mice, 7 days after treatment. ODN-mediated neuroprotection was associated with a reduction of the number of glial fibrillary acidic protein-positive reactive astrocytes and a strong inhibition of the expression of pro-inflammatory genes such as interleukins 1β and 6, and tumor necrosis factor-α. Moreover, ODN blocked the inhibition of the anti-apoptotic gene Bcl-2, and the stimulation of the pro-apoptotic genes Bax and caspase-3, induced by MPTP in the substantia nigra pars compacta. ODN also decreased or even in some cases abolished MPTP-induced oxidative damages, overproduction of reactive oxygen species and accumulation of lipid oxidation products in DA neurons. Furthermore, DBI knockout mice appeared to be more vulnerable than wild-type animals to MPTP neurotoxicity. Taken together, these results show that the gliopeptide ODN exerts a potent neuroprotective effect against MPTP-induced degeneration of nigrostriatal DA neurons in mice, through mechanisms involving downregulation of neuroinflammatory, oxidative and apoptotic processes. ODN may, thus, reduce neuronal damages in PD and other cerebral injuries involving oxidative neurodegeneration.

OriginalsprogEngelsk
TidsskriftCellular and Molecular Life Sciences
Vol/bind75
Udgave nummer11
Sider (fra-til)2075-2091
ISSN1420-682X
DOI
StatusUdgivet - jun. 2018

Fingeraftryk Dyk ned i forskningsemnerne om 'Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater

    Bahdoudi, S., Ghouili, I., Hmiden, M., do Rego, J-L., Lefranc, B., Leprince, J., Chuquet, J., do Rego, J-C., Marcher, A-B., Mandrup, S., Vaudry, H., Tonon, M-C., Amri, M., Masmoudi-Kouki, O., & Vaudry, D. (2018). Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease. Cellular and Molecular Life Sciences, 75(11), 2075-2091. https://doi.org/10.1007/s00018-017-2727-2